topotecan and Glioma
topotecan has been researched along with Glioma in 39 studies
Research
Studies (39)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (28.21) | 18.2507 |
| 2000's | 18 (46.15) | 29.6817 |
| 2010's | 9 (23.08) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Agar, NYR; Al-Dalahmah, O; Argenziano, MG; Banu, MA; Behl, M; Boyett, DM; Bruce, JN; Canoll, P; Catania, V; D'Amico, RS; Furnari, JL; Gill, BJA; Good, L; Grinband, J; Higgins, DMO; Humala, N; Iwamoto, FM; Jambawalikar, S; Lassman, AB; Lignelli, A; Mahajan, A; Marie, T; Mintz, A; Neira, JA; Pereira, B; Petridis, P; Regan, MS; Save, AV; Sims, PA; Spinazzi, EF; Stopka, SA; Sudhakar, TD; Upadhyayula, PS; Welch, MR; Wu, PB; Zacharoulis, S; Zhao, W | 1 |
| Li, Z; Liu, LB; Liu, XB; Liu, YH; Wang, P; Xue, YX; Zhang, FL | 1 |
| Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D | 1 |
| Bruce, JN; DeLaPaz, R; Kennedy, BC; Surapaneni, K; Yanagihara, TK | 1 |
| Babich, JW; Boyd, M; Gaze, MN; Mairs, RJ; McCluskey, AG; Pimlott, SL | 1 |
| Anver, MR; Bonomi, CA; Borgel, SD; Carter, JP; Gehrs, B; Hollingshead, M; Kinders, RJ; Melillo, G; Parchment, R; Raffeld, M; Rapisarda, A; Shoemaker, RH; Uranchimeg, B | 1 |
| Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM | 1 |
| Kivivuori, SM; Lönnqvist, T; Riikonen, P; Saarinen-Pihkala, UM; Valanne, L | 1 |
| Allen, JC; Belasco, JB; Fisher, PG; Janss, AJ; Minturn, JE; Patti, R; Phillips, PC | 1 |
| Bagiella, E; Bruce, JN; Canoll, P; DeLaPaz, RL; Fine, RL; Kennedy, BC; Lai, R; Rosenfeld, SS; Sands, SA; Surapaneni, K; Yanes, CL; Yun, J | 1 |
| Arias-Mendoza, F; Bagiella, E; Brown, T; Bruce, JN; Bruce, SS; Canoll, P; Dashnaw, S; Mohajed, H; Romanov, A; Sebastian, M; Sonabend, AM; Stuart, RM; Yanagihara, T; Yun, J | 1 |
| Anderson, RC; Bruce, JN; Canoll, P; Feldstein, NA; Garvin, J; Kennedy, B; Needle, M; Yanes, CL | 1 |
| Melillo, G; Rapisarda, A; Sausville, EA; Scudiero, DA; Selby, M; Shoemaker, RH; Uranchimeg, B | 1 |
| Ater, J; Geyer, JR; Krailo, MD; Mehta, MP; Needle, MN; Sanghavi, SN | 1 |
| Albani, M; Bucsky, P; Emser, A; Erdlenbruch, B; Gnekow, A; Kühl, J; Längler, A; Peters, O; Völpel, S; Wagner, S; Wolff, JE | 1 |
| Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A | 1 |
| Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Fariselli, L; Fumagalli, L; Gelati, M; Salmaggi, A; Sciacca, F | 1 |
| Bernier-Chastagner, V; Bracard, S; Chastagner, P; Doz, F; Gentet, JC; Grill, J; Kalifa, C; Laithier, V; Lejars, O; Luporsi, E; Margueritte, G; Marie-Cardine, A; Mechinaud, F; Millot, F | 1 |
| Angerson, WJ; Boyd, M; Clark, AM; Cosimo, E; Gaze, MN; Mairs, RJ; McCluskey, AG; Ross, SC | 1 |
| Barberi-Heyob, M; Chastagner, P; Marchal, C; Merlin, JL; Pinel, S; Taghian, A | 1 |
| Blaney, SM; Burger, P; Chintagumpala, MM; Friedman, HS; Holmes, E; Horowitz, ME; Kepner, J; Kun, LE; McCluggage, C; McLendon, RE; Michalski, J; Modrich, PL; Rutka, J; Stewart, CF; Thompson, S; Woo, S | 1 |
| Bankiewicz, KS; Berger, MS; Drummond, DC; Kirpotin, DB; Krauze, MT; Noble, CO; Park, JW; Saito, R | 1 |
| Weller, M | 1 |
| Bjornsti, MA; Chang, CF; Gordon, J; Kerr, DA; Khalili, K | 1 |
| Adamson, PC; Allen, JC; Balis, FM; Berg, SL; Blaney, SM; Heideman, RL; Horowitz, ME; Jakacki, RI; Lange, BJ; Packer, RJ; Phillips, PC; Poplack, DG; Reaman, GH; Sallan, SE | 1 |
| Boothman, DA; Lamond, JP; Mehta, MP | 1 |
| Fueyo, J; Gomez-Manzano, C; Kyritsis, AP; Levin, VA; Martin-Duque, P; Perez-Soler, R; Puduvalli, VK; Yung, WK | 1 |
| Weller, M; Winter, S | 1 |
| Barone, TA; Ciesielski, MJ; Fenstermaker, RA; Greenberg, SJ; Lis, A; Plunkett, RJ; Pollina, J | 1 |
| Arbuck, S; Cokgor, I; Fields, S; Friedman, AH; Friedman, HS; Graden, D; Houghton, PJ; Kerby, T; McLendon, RE; Zilisch, JE | 1 |
| Dooley, NP; Gladson, CL; Kyritsis, AP; Rao, JS; Uhm, JH | 1 |
| Loos, WJ; Schellens, JH; Straathof, CS; van den Bent, MJ; Vecht, CJ | 1 |
| Bom, D; Burke, TG; Curran, DP; Erff, M; Pollack, IF; Strode, JT | 1 |
| Bartussek, C; Naumann, U; Weller, M | 1 |
| Bernath, AM; Buckner, JC; Burch, PA; Cascino, TL; Kugler, JW; Nair, S; Novotny, P; Pfeifle, DM; Scheithauer, BW; Tschetter, LK | 1 |
| Bruce, JN; Chakrabarti, I; Chi, JH; Hall, JS; Hurley, PT; Kaiser, MG; Parsa, AT | 1 |
| Gooley, T; Hawkins, D; Lindsley, K; Matthay, KK; Park, JR; Sanders, JE; Slattery, J; Villablanca, JG | 1 |
| Bruce, JN; Chakrabarti, I; Fine, RL; Hall, JS; Kaiser, MG; Parsa, AT | 1 |
| Naumann, U; Rieger, J; Schmidt, F; Weller, M; Wischhusen, J | 1 |
Trials
10 trial(s) available for topotecan and Glioma
| Article | Year |
|---|---|
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.
Topics: Convection; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Topotecan | 2022 |
A phase II study of metronomic oral topotecan for recurrent childhood brain tumors.
Topics: Brain Neoplasms; Brain Stem Neoplasms; Child; Disease-Free Survival; Ependymoma; Female; Glioma; Humans; Male; Neuroectodermal Tumors, Primitive; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2011 |
A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952.
Topics: Adolescent; Brain Stem Neoplasms; Child; Child, Preschool; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Radiation-Sensitizing Agents; Survival Rate; Topotecan | 2003 |
Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Glioma; Humans; Male; Topotecan; Treatment Outcome | 2004 |
Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.
Topics: Adolescent; Age Factors; Brain Stem Neoplasms; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Risk Assessment; Survival Analysis; Time Factors; Topotecan; Treatment Outcome | 2005 |
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carrier Proteins; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Immunohistochemistry; Male; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm, Residual; Nuclear Proteins; Procarbazine; Survival Analysis; Topotecan | 2006 |
Phase II evaluation of topotecan for pediatric central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Infant; Infusions, Intravenous; Male; Topotecan | 1996 |
Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Topotecan; Treatment Outcome | 1999 |
A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Topotecan | 2000 |
Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
Topics: Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Glioma; Hematopoietic Stem Cell Transplantation; Humans; Infant; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan | 2000 |
Other Studies
29 other study(ies) available for topotecan and Glioma
| Article | Year |
|---|---|
Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells.
Topics: Apoptosis; Brain Neoplasms; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Glioma; Humans; Naphthoquinones; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Topotecan | 2013 |
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studies; Celecoxib; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Child, Preschool; Etoposide; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Grading; Prognosis; Pyrazoles; Quality of Life; Remission Induction; Sulfonamides; Survival Rate; Thalidomide; Topotecan | 2014 |
Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma.
Topics: Adult; Aged; Antineoplastic Agents; Blood Volume; Brain Neoplasms; Cerebrovascular Circulation; Convection; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Predictive Value of Tests; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Burden | 2015 |
Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; Glioma; Mice; Mice, Nude; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Radiopharmaceuticals; Topotecan; Treatment Outcome | 2008 |
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Proliferation; DNA Damage; Drug Synergism; Female; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Luciferases; Mice; Mice, Nude; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Celecoxib; Child; Child, Preschool; Disease Progression; Etoposide; Glioma; Humans; Pilot Projects; Pyrazoles; Quality of Life; Radiation-Sensitizing Agents; Sulfonamides; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome | 2011 |
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan.
Topics: Adult; Aged; Attention; Convection; Drug Administration Schedule; Drug Delivery Systems; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Memory; Middle Aged; Neurologic Examination; Neuropsychological Tests; Prospective Studies; Quality of Life; Reaction Time; Supratentorial Neoplasms; Surveys and Questionnaires; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Topotecan; Young Adult | 2011 |
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump.
Topics: Animals; Brain Neoplasms; Contrast Media; Convection; Drug Delivery Systems; Gadolinium DTPA; Glioma; Humans; Image Processing, Computer-Assisted; Infusion Pumps, Implantable; Infusions, Subcutaneous; Liposomes; Magnetic Resonance Imaging; Male; Swine; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2011 |
Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children.
Topics: Antineoplastic Agents; Biopsy; Brain; Brain Stem Neoplasms; Child, Preschool; Combined Modality Therapy; Convection; Drug Delivery Systems; Fatal Outcome; Female; Gait Disorders, Neurologic; Glioma; Humans; Image Processing, Computer-Assisted; Karnofsky Performance Status; Magnetic Resonance Imaging; Nervous System Diseases; Radiography; Topotecan; Treatment Outcome | 2013 |
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
Topics: Antineoplastic Agents; Camptothecin; DNA-Binding Proteins; DNA, Neoplasm; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Gene Expression; Glioma; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Lymphokines; Nuclear Proteins; Promoter Regions, Genetic; Response Elements; RNA, Messenger; Topotecan; Transcription Factors; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cisplatin; Dacarbazine; Doxorubicin; Drug Interactions; Glioma; Humans; Temozolomide; Topotecan; Tumor Cells, Cultured | 2004 |
In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Combined Modality Therapy; Glioma; Humans; Membrane Glycoproteins; Nervous System Neoplasms; Radiation, Ionizing; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Tumor Necrosis Factor-alpha | 2005 |
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Comet Assay; DNA Damage; DNA Fragmentation; DNA, Complementary; Glioma; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Time Factors; Topotecan; Transfection | 2005 |
Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Glioma; Humans; Mice; Mice, Nude; Topotecan; Transplantation, Heterologous | 2006 |
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dose-Response Relationship, Drug; Drug Delivery Systems; Glioma; Humans; Liposomes; Male; Rats; Rats, Nude; Topotecan; Xenograft Model Antitumor Assays | 2006 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Genetic Markers; Glioma; Humans; Lymphoma; Prognosis; Promoter Regions, Genetic; Temozolomide; Topotecan; Tumor Suppressor Proteins | 2008 |
Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin.
Topics: Antineoplastic Agents; Camptothecin; Chloramphenicol O-Acetyltransferase; DNA Replication; DNA Topoisomerases, Type I; Gene Expression Regulation, Viral; Glioma; Humans; JC Virus; Neuroglia; Promoter Regions, Genetic; Recombinant Fusion Proteins; Regulatory Sequences, Nucleic Acid; Topotecan; Transfection | 1993 |
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Central Nervous System Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Glioma; Humans; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy.
Topics: Adenoviridae; Antineoplastic Agents; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p16; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase; Glioma; Humans; Paclitaxel; Recombinant Proteins; Time Factors; Topotecan; Transfection | 1998 |
Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Fas Ligand Protein; fas Receptor; Glioma; Humans; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins c-bcl-2; RNA; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Survival; Enzyme Inhibitors; Glioma; Humans; Infusions, Parenteral; Rats; Rats, Nude; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1998 |
Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death.
Topics: Antibodies, Monoclonal; Apoptosis; bcl-X Protein; Cell Survival; Fibronectins; Glioma; Humans; In Situ Nick-End Labeling; Integrins; Proto-Oncogene Proteins c-bcl-2; Receptors, Fibronectin; Receptors, Vitronectin; Topotecan; Tumor Cells, Cultured; Vitronectin | 1999 |
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.
Topics: Animals; Brain; Brain Neoplasms; Dexamethasone; Female; Glioma; Rats; Rats, Inbred F344; Reference Values; Tissue Distribution; Topotecan | 1999 |
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Genes, p53; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Cell Death; Cell Division; Cisplatin; Clone Cells; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression Regulation, Neoplastic; Genes, Dominant; Glioma; Humans; In Vitro Techniques; Paclitaxel; Point Mutation; Radiotherapy; Teniposide; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vincristine | 1999 |
Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy.
Topics: Animals; Antibody Formation; Antineoplastic Agents; Brain Neoplasms; Cell Division; Glioma; Immunity, Cellular; Immunotherapy; Male; Neoplasm Transplantation; Rats; Rats, Inbred F344; Rats, Wistar; Survival Analysis; Topotecan; Tumor Cells, Cultured | 2000 |
Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model.
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Glioma; Injections, Intraperitoneal; Neoplasm Transplantation; Rats; Rats, Wistar; Tissue Distribution; Topotecan; Tumor Cells, Cultured | 2000 |
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.
Topics: Antineoplastic Agents; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; Genes, p53; Glioma; Humans; RNA, Messenger; Topotecan; Tumor Cells, Cultured | 2001 |